Blood Tests to Monitor Brilinta (Ticagrelor)
Routine laboratory monitoring for Brilinta includes hemoglobin/hematocrit to detect bleeding, serum creatinine to monitor renal function, and serum uric acid levels, though no specific blood test is required to measure drug levels or adjust dosing in clinical practice.
Laboratory Monitoring Parameters
Based on the FDA drug label, the following laboratory abnormalities occur with Brilinta and warrant monitoring 1:
Hemoglobin and Hematocrit
- Monitor for bleeding complications - the primary safety concern with Brilinta
- Check baseline values before initiation
- Recheck if clinical bleeding is suspected or with signs/symptoms of anemia
- Major bleeding is defined as a hemoglobin drop ≥3 g/dL or hematocrit fall ≥9%
- Fatal/life-threatening bleeding involves hemoglobin drop >5 g/dL or hematocrit fall ≥15%
Serum Creatinine
- Monitor renal function periodically 1
- In the PLATO trial, 7.4% of patients on ticagrelor 90 mg had >50% increase in serum creatinine versus 5.9% on clopidogrel
- These increases typically do not progress with ongoing treatment and often decrease with continued therapy
- Evidence of reversibility occurs upon discontinuation, even in patients with the greatest increases
- In PEGASUS trial with ticagrelor 60 mg, approximately 4% had creatinine increases >50%, similar to aspirin alone
Serum Uric Acid
- Check if gout symptoms develop 1
- Uric acid levels increased approximately 0.6 mg/dL from baseline with ticagrelor 90 mg (versus 0.2 mg/dL with clopidogrel)
- With ticagrelor 60 mg, levels increased approximately 0.2 mg/dL from baseline
- The difference disappears within 30 days of discontinuing treatment
- Gout occurred in 1.5% on ticagrelor 60 mg versus 1.1% on aspirin alone in PEGASUS
Platelet Function Testing
Routine platelet function testing is NOT recommended for dose adjustment 2. The 2017 ESC guidelines explicitly state that "routine platelet function testing to adjust antiplatelet therapy before or after elective stenting is not recommended" 2.
However, platelet function testing may have specific roles in select situations:
When Platelet Function Testing May Be Considered
- Switching from clopidogrel to ticagrelor: The ESC guidelines recommend administering a 600 mg loading dose of clopidogrel when switching, with possible monitoring to exclude poor/non-responders 3
- Pre-operative assessment: Research shows platelet function monitoring can identify patients with early platelet recovery who may undergo urgent CABG earlier than the conventional 5-7 day washout period 4
- Available assays that correlate with ticagrelor levels include VerifyNow P2Y12, VASP assay, and Multiplate analyzer, all showing comparably strong negative correlations with drug concentrations 5
Special Monitoring Situations
Triple Therapy with Anticoagulation
When ticagrelor is combined with oral anticoagulation (e.g., for LV thrombus), strict INR monitoring is required if using warfarin 3. Consider switching to clopidogrel to reduce bleeding risk in this scenario.
Pre-Surgical Planning
If urgent surgery is needed, ticagrelor should be withheld 24-72 hours before elective procedures 2. Platelet function testing with VerifyNow can guide timing of surgery by identifying earlier platelet recovery 4.
Common Pitfalls to Avoid
- Do not routinely measure ticagrelor drug levels - this is not commercially available or clinically useful for standard monitoring
- Do not use platelet function testing for routine dose adjustment - this contradicts guideline recommendations 2
- Do not ignore creatinine increases - while they often stabilize, monitor trends especially in patients with baseline renal impairment
- Do not forget to monitor for clinical bleeding - laboratory monitoring is secondary to clinical assessment for signs of hemorrhage
The monitoring strategy should focus on clinical assessment for bleeding combined with periodic laboratory checks of hemoglobin, creatinine, and uric acid as clinically indicated, rather than specialized platelet function or drug level testing 1.